|Awarded On||August 19, 2020|
|Title||Rational Combination Therapy for Aggressive Double-Hit Lymphoma|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Yulin Li|
Double-hit lymphoma (DHL) is a one of the most refractory cancer types. DHLs have several aberrant cancer proteins, including MYC, BCL2 and/or BCL6. Due to simultaneous activation of these cancer-related genes, DHLs do not respond to the current chemotherapy or immunotherapy. Treatment of DHL currently is an unmet medical need. Treatment of DHL is therefore an unmet medical need, which requires a combination of multiple therapeutic approaches.
Targeted therapy contributes to the shrinkage of the tumor burden by directly aiming at cancer cells. However, tumor cells that have lost their response to the drug, will regrow causing a tumor relapse. On the other hand, immunotherapy engages body's ...